Jin Yaoyao Pharmaceutical Co., Ltd.: Its subsidiary Jin Yaoyao Heping has obtained the registration certificate for the fluorometholone eye drops.

Tianjin Pharmaceutical Industry Announcement, its subsidiary Tianjin He Ping Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of difluoropinid eye drops. This drug is mainly used to treat inflammation and pain related to eye surgery. Tianjin He Ping has accumulated research and development costs of approximately 53.2734 million yuan in this project. Currently, difluoropinid eye drops are the first generic drug in China. Global sales in 2023 and 2024 are expected to be $33 million and $24 million, respectively.